South San Francisco–based Neuron23 has started the first-in-human Phase 1 trial of NEU-723 for the treatment of Parkinson’s disease. NEU-723 is a highly potent and selective leucine-rich repeat kinase 2 (LRRK2) inhibitor. This clinical trial will evaluate the safety, tolerability and pharmacokinetics of NEU-723 in healthy volunteers. A targeted approach The company has also collaborated…
Neuron23 names chief medical officer
The early-stage biotech Neuron23 has appointed Dr. Sam Jackson as its first chief medical officer. South San Francisco, California–based Neuron23 specializes in developing precision medicines for genetically-defined neurological and immunological diseases. Jackson is a board-certified emergency physician with fellowship training in medical toxicology. “I am thrilled to welcome Dr. Jackson to our growing Neuron23 leadership…